Source: Longevity.Technology

CaseBioscience® has joined a multidisciplinary team awarded $7.3 million by ARPA-H to develop innovative methods for cell therapy product storage.

MiNK Therapeutics (INKT) has been selected to provide its agenT-797 cell platform for an ARPA-H-funded team developing room-temperature cell therapy storage technologies.MiNK joins the Reversible Ambient Biostabilization team led by The Charles Stark Draper Laboratory within ARPA-H’s four-year BioStabilization Systems program. ARPA-H has committed up to $87 million across the program, which aims to move living medicines from cryogenic storage near -196°C toward storage near 21°C. This is program-wide funding, not a disclosed award to MiNK. MiNK will contribute its clinical-stage immune-cell platform, manufacturing infrastructure and development expertise. The team plans to use AI-assisted experiments and freeze-assisted droplet drying to develop and evaluate stabilization technologies.

The Advanced Research Projects Agency for Health (ARPA-H) supports transformative research to drive biomedical and health breakthroughs ranging from molecular to societal to provide transformative hea...